UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 14 von 30
Datensatz exportieren als...
BibTeX
Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
Movement disorders, 2021-02, Vol.36 (2), p.503-508
Shribman, Samuel
Heller, Carolin
Burrows, Maggie
Heslegrave, Amanda
Swift, Imogen
Foiani, Martha S.
Gillett, Godfrey T.
Tsochatzis, Emmanuel A.
Rowe, James B.
Gerhard, Alex
Butler, Chris R.
Masellis, Mario
Bremner, Fion
Martin, Alison
Jung, Lynne
Cook, Paul
Zetterberg, Henrik
Bandmann, Oliver
Rohrer, Jonathan D.
Warner, Thomas T.
2021
Details
Autor(en) / Beteiligte
Shribman, Samuel
Heller, Carolin
Burrows, Maggie
Heslegrave, Amanda
Swift, Imogen
Foiani, Martha S.
Gillett, Godfrey T.
Tsochatzis, Emmanuel A.
Rowe, James B.
Gerhard, Alex
Butler, Chris R.
Masellis, Mario
Bremner, Fion
Martin, Alison
Jung, Lynne
Cook, Paul
Zetterberg, Henrik
Bandmann, Oliver
Rohrer, Jonathan D.
Warner, Thomas T.
Titel
Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
Ist Teil von
Movement disorders, 2021-02, Vol.36 (2), p.503-508
Ort / Verlag
Hoboken, USA: John Wiley & Sons, Inc
Erscheinungsjahr
2021
Link zum Volltext
Quelle
Wiley Online Library All Journals
Beschreibungen/Notizen
Background Outcomes are unpredictable for neurological presentations of Wilson's disease (WD). Dosing regimens for chelation therapy vary and monitoring depends on copper indices, which do not reflect end‐organ damage. Objective To identify a biomarker for neurological involvement in WD. Methods Neuronal and glial‐specific proteins were measured in plasma samples from 40 patients and 38 age‐matched controls. Patients were divided into neurological or hepatic presentations and those with recent neurological presentations or deterioration associated with non‐adherence were subcategorized as having active neurological disease. Unified WD Rating Scale scores and copper indices were recorded. Results Unlike copper indices, neurofilament light (NfL) concentrations were higher in neurological than hepatic presentations. They were also higher in those with active neurological disease when controlling for severity and correlated with neurological examination subscores in stable patients. Conclusion NfL is a biomarker of neurological involvement with potential use in guiding chelation therapy and clinical trials for novel treatments. © 2020 University College London. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185, 1531-8257
eISSN: 1531-8257
DOI: 10.1002/mds.28333
Titel-ID: cdi_swepub_primary_oai_gup_ub_gu_se_299270
Format
–
Schlagworte
Biomarkers
,
Brief Report
,
Chelation
,
Chelation therapy
,
Clinical trials
,
Copper
,
Copper - analysis
,
Hepatolenticular Degeneration
,
Humans
,
Intermediate Filaments - chemistry
,
London
,
Movement disorders
,
neurofilament light
,
Neurological diseases
,
Neuronal-glial interactions
,
Neurosciences
,
Neurovetenskaper
,
Plasma - chemistry
,
Regular Issue
,
Wilson's disease
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX